3Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363: 2022-2031.
4Hasford J, Mimran A, Simons WR. A population-based european cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens, 2002, 16: 569-575.
5Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther, 1998, 20: 671-681.
6Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens, 2001, S291-S295.
7Shimada K, Kawamoto A, Matsubayashi K, et al. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens, 1992, 10: 875-878.
8Lacourciere Y, Lenis J, R Orchard, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit, 1998, 3: 295-302.
9Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA, 2003, 289: 2560-2571.
10MacKay JH, Arcuri KE, Goldberg A. I, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med, 1996, 156: 278-285.
3Lauer MS,Okin PM, Larson MG, et al. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study [ J]. Circulation, 1996,93 ( 8 ) : 1520.
4Dresing TJ, Blackstone EH, Pashkow FJ, et al. Useful- ness of impaired chonotropic response to exercise as a pre-dictor of mortality, independent of the severity of coronary artery disease [ J ]. Am J Cardiol, 2000,86 (6) :602.
5Vallebona A, Gigli G, Orlandi S, et al. Heart rate re- sponse to graded exercise correlates with aerobic and venti- latory capacity in patients with heart failure [ J ]. Clin Car- diol, 2005,28 ( 1 ) :25.
6Azarbal B, Hayes SW, Lewin HC, et al. The incremental prognostic value of percentage of heart rate reserve achieved over myocardial perfusion single-photon emission computed tomography in the prediction of cardiac death and all-cause mortality: superiority over 85% of maximal age-predicted heart rate[J]. J Am Coll Cardiol, 2004,44(2):423.
7Callaghan B C,Cherg H T,Stables C L,et al.Diabetic neuropathy:clinical manifestations and current treatments[J].Lancet Neurol,2012,11 (6):521-534.
8Habib A A,Brannagan T H.Therapeutic strategies for diabetic neuropathy[J].Curr Neurol Neurosci Rep,2010,10(2):92-100.
9Lefrandt J D,Smit A J,Zeebregts C J,et al.Autonomic dysfunction in diabetes:a consequence of cardiovascular damage[J].Curr diabetes Rev,2010,6(6):348-358.
10Viggiano A,Vicidomini C,Monda M,et al.Fast and low-cost analysis of heart rate variability reveals vegetative alterations in noncomplicated diabetic patients[J].J Diabetes Complcations,2009,23 (2):119-123.
